eMIMS New Product
New drug - Tasigna
23-Jun-08
Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome positive chronic myelogenous leukaemia (CML).
Treatment is indicated for adults with chronic-phase and accelerated-phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
Further information: Novartis 01276 692255
Quick search - use * for an abbreviated search, eg nico*
Tools
Latest Guidelines
- Osteoporotic Fragility Fractures in Postmenopausal Women: Primary Prevention (NICE)
- Osteoporotic Fragility Fractures in Postmenopausal Women: Secondary Prevention (NICE)
- VTE, Prevention of: Dabigatran (NICE)
- Influenza Prophylaxis: Oseltamivir, Amantadine and Zanamivir (NICE)
- Hepatitis B, Chronic: Entecavir (NICE)
GMS Contract Action Plan
Jobs
Job of the Week
- Saturday Morning Locum North East England
- Full time salaried GP South East England
- Salaried GP
- Salaried GPs South East England
- Part-Time Salaried GP South East England
- GP Positions North West England
- General Practice Placements Central London
- Salaried GP West Midlands
- Part Time Salaried GP South West England
- Salaried Doctor East of England
Comments
Only registered users may comment. Log in now or register for a free account.